Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH: Seretide Survival Study in COPD
NCT00268216Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2000
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 44
01
Overview
Phase 3, randomised, double-blind trial of salmeterol + fluticasone in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: All cause mortality at 3 years. Started Sep 2000; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00268216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268216.